Heron Therapeutics, Inc. (HRTX)
0.3208
0.00 (0.00%)
USD |
NASDAQ |
Aug 25, 12:16
Heron Therapeutics EPS Diluted (Quarterly) : -0.0288 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0288 |
| March 31, 2026 | -0.0428 |
| December 31, 2025 | -0.0157 |
| September 30, 2025 | -0.1027 |
| June 30, 2025 | -0.0155 |
| March 31, 2025 | 0.0134 |
| December 31, 2024 | 0.0239 |
| September 30, 2024 | -0.0317 |
| June 30, 2024 | -0.0606 |
| March 31, 2024 | -0.0209 |
| December 31, 2023 | -0.0714 |
| September 30, 2023 | -0.1725 |
| June 30, 2023 | -0.3513 |
| March 31, 2023 | -0.2748 |
| December 31, 2022 | -0.1668 |
| September 30, 2022 | -0.3751 |
| June 30, 2022 | -0.5504 |
| March 31, 2022 | -0.6256 |
| December 31, 2021 | -0.5359 |
| September 30, 2021 | -0.5143 |
| June 30, 2021 | -0.6197 |
| March 31, 2021 | -0.5757 |
| December 31, 2020 | -0.6838 |
| September 30, 2020 | -0.6409 |
| June 30, 2020 | -0.6081 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.5705 |
| December 31, 2019 | -0.65 |
| September 30, 2019 | -0.4202 |
| June 30, 2019 | -0.6313 |
| March 31, 2019 | -0.8035 |
| December 31, 2018 | -0.6347 |
| September 30, 2018 | -0.4928 |
| June 30, 2018 | -0.54 |
| March 31, 2018 | -0.81 |
| December 31, 2017 | -1.09 |
| September 30, 2017 | -0.77 |
| June 30, 2017 | -0.80 |
| March 31, 2017 | -1.00 |
| December 31, 2016 | -1.22 |
| September 30, 2016 | -1.24 |
| June 30, 2016 | -1.17 |
| March 31, 2016 | -0.92 |
| December 31, 2015 | -0.87 |
| September 30, 2015 | -0.63 |
| June 30, 2015 | -0.74 |
| March 31, 2015 | -0.70 |
| December 31, 2014 | -0.71 |
| September 30, 2014 | -0.66 |
| June 30, 2014 | -0.78 |
| March 31, 2014 | -0.74 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Praxis Precision Medicines, Inc. | -2.874 |
| Tonix Pharmaceuticals Holding Corp. | -2.438 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.489M |
| Revenue (Quarterly) | 37.67M |
| Total Expenses (Quarterly) | 43.16M |
| Enterprise Value | 167.90M |
| Gross Profit Margin (Quarterly) | 69.28% |
| Profit Margin (Quarterly) | -14.57% |
| Earnings Yield | -59.23% |
| Normalized Earnings Yield | -44.33 |